LUX-Lung: determining the best EGFR inhibitor in NSCLC?

A partir de données portant sur 345 et 364 patients atteints d'un adénocarcinome du poumon EGFR+ et inclus respectivement dans les essais de phase III LUX-Lung 3 et LUX-Lung 6, cette étude évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'afatinib en fonction du type de mutation du gène EGFR

Résumé en anglais

The frequency and characteristics of EGFR mutations in patients with non-small-cell lung cancer, and their correlation with outcome in patients receiving tyrosine kinase inhibitors, have been previously reported in the scientific literature. In The Lancet Oncology, James Chih-Hsin Yang and colleagues now report overall survival (a secondary endpoint) from two phase 3 trials: LUX-Lung 3 (n=345) and LUX-Lung 6 (n=364). Both trials compared afatinib, a second-generation EGFR tyrosine kinase inhibitor, with platinum-based first-line chemotherapy in patients with lung adenocarcinoma harbouring EGFR mutations.